cme.medlearning.de - CME Logo

Literaturliste

Prävalenz, Ätiologie, Pathophysiologie, Verlauf

  1. Mulhall JP, Creech SD, Boorjian SA et al. Subjective and objective analysis of the prevalence of Peyronie‘s disease in a population of men presenting for prostate cancer screening. J Urol 2004; 171(6 Pt 1):2350-3
  2. Schwarzer U, Sommer F, Klotz T et al. The prevalence of Peyronie‘s disease: results of a large survey. BJU Int 2001; 88:727-30
  3. Sommer F, Schwarzer U, Wassmer G et al. Epidemiology of Peyronie’s disease. Int J Impot Res 2002 Oct;14(5):379-83
  4. Gonzalez-Cadavid NF, Rajfer J. Mechanisms of Disease: new insights into the cellular and molecular pathology of Peyronie’s disease. Nat Clin Pract Urol 2005 Jun;2(6):291-7
  5. Devine CJ Jr, Somers KD, Jordan SG et al. Proposal: trauma as the cause of the Peyronie’s lesion. J Urol 1997;157:285-90
  6. Zimmermann R. Pathophysiologie der Induratio penis plastica: Aktueller Kenntnisstand, J Urol Urogynäkol 2008;15(2):22-9
  7. Mulhall JP Schiff J, Guhring P. An analysis of the natural history of Peyronie‘s disease. J Urol 2006;175:2115-8

Übersichtssarbeiten

  1. Hauptmann A. et al. Induratio penis plastice (Ipp), Diagnostik und Therapie. Urologe 2011;50:609-20
  2. Schorn H. Induratio penis plastic. Wie Erfolg versprechend sind konservative Therapien? Andrologen.info, Feb 2010

Ipp und Diabetes mellitus

  1. Kenderici M, Trost L, Sikka SC, Hellstrom WJ. Diabetes mellitus is associated with severe Peyronie‘s disease; BJU International 2007;99:383-6
  2. Tefekli A. Kandirali E, Erol B, Tunc M, Kadioglu A. Peyronies disease: a silent consequence of diabetes mellitus. Asian J Androl 2006;8(1):75-9

Therapieguidelines

  1. Ralph D, Gonzales-Cadavid N, Mirone V, Perovic S, Sohn M, Usta M, Levine L. The Management of Peyronie‘s Disease: Evidence-based 2010 Guidelines. J Sex med 2010;7:2359-74
  2. Wespes E, Hatzimouratidis K, Eardley I, Giuliano F, Hatzichristou D, Moncada I, Salonia A, Vardi Y. Guidelines on Penile Curvature. European Association of Urology 2012, Feb, 2012

Konservative Therapie der Ipp

  1. Weidner W, Hauck EW, Schnitker J. Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie’s disease: a prospective, placebo-controlled, randomized study. Eur Urol 2005 Apr;47(4):530-5
  2. Bennett NE, Guhring P, Mulhall JP. Intralesional verapamil prevents the progression of Peyronie’s disease. Urology 2007 Jun;69(6):1181-4
  3. Cavallini G, Modenini F, Vitali G. Open preliminary randomized prospective clinical trial of efficacy and safety of three different verapamil dilutions for intraplaque therapy of Peyronie’s disease. Urology 2007 May;69(5):950-4
  4. Shirazi M, Haghpanah AR, Badiee M et al. Effect of intralesional verapamil for treatment of Peyronie’s disease: a randomized single-blind, placebo-controlled study. Int Urol Nephrol 2009;41(3):467-71
  5. Hellstrom WJ, Kendirci M, Matern R et al. Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie’s disease. J Urol 2006 Jul;176(1):394-8
  6. Jordan GH. The use of intralesional clostridial collagenase injection therapy for Peyronie’s disease: a prospective, single-center, non-placebo-controlled study. J Sex Med 2008 Jan;5(1):180-7
  7. Fitch WP 3rd, Easterling WJ, Talbert RL et al. Topical verapamil HCl, topical trifluoperazine, and topical magnesium sulfate for the treatment of Peyronie’s disease--a placebo-controlled pilot study. J Sex Med 2007 Mar;4(2):477-84
  8. Di Stasi SM, Giannantoni A, Stephen RL et al. A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie’s disease. J Urol 2004 Apr;171(4):1605-8
  9. Greenfield JM, Shah SJ, Levine LA. Verapamil versus saline in electromotive drug administration for Peyronie’s disease: a double-blind, placebo controlled trial. J Urol 2007 Mar;177(3):972-5
  10. Palmieri A, Imbimbo C, Longo N et al. A first prospective, randomized, double-blind, placebocontrolled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie’s disease. Eur Urol 2009 Aug;56(2):363-9

Operation

  1. Montorsi F, Adaikan G, Becher E et al. Summary of the recommendations on sexual dysfunctions in men. J Sex Med 2010 Nov;7(11):3572-88
  2. Kendirci M, Hellstrom WJ. Critical analysis of surgery for Peyronie’s disease. Curr Opin Urol 2004; 14:381-8
  3. Mulhall J, Anderson M, Parker M. A surgical algorithm for men with combined Peyronie’s disease and erectile dysfunction: functional and satisfaction outcomes. J Sex Med 2005 Jan;2(1):132-8

Erektile Dysfunktion

  1. Rosen RC, Riley A, Wagner G et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997 Jun;49(6):822-30

Sonstiges

  1. Muller A, Mulhall JP. Peyronie’s disease intervention trials: methodological challenges and issues. J Sex Med 2009 Mar;6(3):848-61
  2. Mulhall JP et al. Peyronie‘s disease in teenagers. J Sex Med. 2012 Jan;9(1):302-8

 Back to Top


Valid XHTML 1.0 Transitional